The Club interviews Jesse Karmazin, CEO, to find out more about the trial, the FDA warning, and the relaunch
CEO of the blood transfusion company Ambrosia.
Visit website: https://everipedia.org/wiki/lang_en/jesse-karmazin
See also: Ambrosia - Offers young blood plasma transfers after running a trial in 2016-18
Jesse Karmazin Blog Posts
Jesse Karmazin News
Ambrosia young blood plasma treatments relaunched
OneZero - 08-Nov-2019
No further clinical trials planned, but some interesting results from initial trialRead more...
Young blood as a key to living longer
Wired - 09-May-2018
GDF11 is a protein in the blood, which can stimulate cell growth and repairRead more...
Young blood reduces ageing biomarkers in humans
New Scientist - 31-May-2017
Update on Ambrosia trial that gives blood plasma from under 25s to older people. Recipients have...Read more...
Young blood antiaging trial raises questions
Science - 01-Aug-2016
Ambrosia (https://www.ambrosiaplasma.com/) young plasma trial is open to anyone 35 and older. Pa...Read more...